Last $0.69 USD
Change Today +0.0098 / 1.44%
Volume 131.6K
CYCC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

cyclacel pharmaceuticals inc (CYCC) Key Developments

Cyclacel Pharmaceuticals, Inc. Declares Quarterly Cash Dividend on Preferred Stock , Payable on February 1, 2015

On December 3, 2014, the Board of Directors of Cyclacel Pharmaceuticals, Inc. declared a quarterly cash dividend in the amount of $0.15 per share on the Company’s 6% Convertible Exchangeable Preferred Stock. The cash dividend will be payable on February 1, 2015 and paid on February 2, 2015 to the holders of record of the Preferred Stock as of the close of business on January 5, 2015.

Cyclacel Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter Ended September 30, 2014

Cyclacel Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter ended September 30, 2014. For the quarter, the company reported total revenues of $735,000 against $309,000 a year ago. Operating loss was $5,670,000 against $5,795,000 a year ago. Loss from continuing operations before taxes was $5,661,000 against $5,746,000 a year ago. Net loss from continuing operations was $4,911,000 or $0.22 per diluted share against $5,016,000 or $0.32 per diluted share a year ago. Net loss applicable to common shareholders was $4,957,000 or $0.22 per diluted share against $5,728,000 or $0.32 per diluted share a year ago. The reported $15 million of net cash used in operating activities.

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 11, 2014

Cyclacel Pharmaceuticals, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 11, 2014

Cyclacel Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 11, 2014

Cyclacel Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 11, 2014

Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the Seamless Phase 3 Trial of Sapacitabine in AML

Cyclacel Pharmaceuticals, Inc. announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 SEAMLESS study in acute myeloid leukemia (AML) has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 317 randomized patients with at least 60 days of follow-up and noted that no safety or efficacy concerns were identified. SEAMLESS is a Phase 3, randomized, registration-directed study of oral sapacitabine capsules in elderly (70 years or older) patients with AML who are unfit for or have refused intensive chemotherapy. The primary endpoint is overall survival. SEAMLESS is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The DSMB will perform an interim analysis for futility once half of the required events have been observed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYCC:US $0.69 USD +0.0098

CYCC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYCC.
View Industry Companies
 

Industry Analysis

CYCC

Industry Average

Valuation CYCC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.9x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYCLACEL PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.